Amaxa-Promega Partnership to Enable Simplified Monitoring of Cell Signaling Events in Stem Cells, Cancer Cells and Primary Cells

Amaxa and Promega have announced an agreement to develop applications that will provide cell biologists broader access to monitor cell signaling events in difficult-to-transfect cells, including stem cells, cancer cells and primary cells. Integrating their technologies in luminescence-based assays and transfection methodologies will simplify transfection of reporter genes and assay development in these difficult-to-transfect cell types.

Amaxa’s Nucleofector® Technology enables unprecedented transfection capability and consistent performance in applications involving more biologically relevant mammalian systems, such as primary cells and stem cells.

“With the Nucleofector® Technology, transfection efficiencies of up to 95% using DNA and 99% using siRNA oligonucleotides can be achieved in difficult-to-transfect cells. Thus, the combination of Promega and Amaxa technologies will enable researchers to obtain much more significant results with physiologically relevant cells rather than more artificial cell lines”, said Rainer Christine, co-founder and CEO, Amaxa. Introducing the Nucleofector® 96-well Shuttle® System has expanded use of the technology to high-throughput applications such as drug screening.

Promega luciferase reporter gene vectors and assay reagents are the most sensitive bioluminescent tools to monitor cell signaling events and provide the widest dynamic range in reporter assay technologies.

“Luciferase reporters are routinely used to monitor gene expression and are ideal tools for high-throughput screening, RNAi-mediated gene regulation and detection of cellular metabolism and viability.

The combination of Promega’s luciferase products and Amaxa’s technology will enable the generation of stable cell lines and bioluminescent cell-based assays even for primary cells” said John Watson, Director of Cellular Analysis, Promega.